TopoTarget A/S Release: Belinostat Gets EU Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma
10/15/2012 9:45:35 AM
Copenhagen, October 15, 2012 -- On October 15, 2012, the European Commission granted Topotarget A/S an Orphan Drug Designation for belinostat, its novel histone deacetylase (HDAC) inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL). PTCL is a rare form of non-Hodgkin’s lymphoma.
comments powered by